No Fluff. Just Sources.
Practical Guide

GLP-1 Drug Interactions: What You Can & Can't Take Together

Complete interaction guide for insulin, sulfonylureas, birth control, thyroid medications, blood thinners, and alcohol—based on FDA prescribing information and 2025 ADA guidelines.

December 2025 12 min read 18 Sources

GLP-1 medications don't interact with most drugs the way traditional medications do—they don't inhibit liver enzymes or compete for protein binding. Instead, their primary interaction mechanism is physiological: they slow gastric emptying, which affects how quickly other oral medications are absorbed.

This guide covers every major interaction category, from high-risk diabetes medication combinations to the tirzepatide-specific warning about birth control.

High-Risk Interactions: Diabetes Medications

The most dangerous interactions involve other glucose-lowering drugs. GLP-1s stimulate insulin secretion only when blood glucose is elevated (glucose-dependent), but combining them with drugs that force insulin release regardless of glucose levels creates hypoglycemia risk.

💉
Insulin (All Types)
High Risk — Dose Reduction Required
The Risk

Clinical trials show symptomatic hypoglycemia in 16.7% to 29.8% of patients using GLP-1s with insulin. The GLP-1's effect on gastric emptying and endogenous insulin makes the previous insulin dose excessive.

Clinical Protocol: Reduce total daily insulin by approximately 20% when starting a GLP-1, especially if HbA1c is <8.0% or patient has hypoglycemia history. Use CGM or frequent SMBG during titration.
💊
Sulfonylureas (Glipizide, Glyburide, Glimepiride)
High Risk — Discontinuation Preferred
The Risk

Sulfonylureas force insulin release regardless of blood glucose levels—fundamentally at odds with GLP-1s' "smart" glucose-dependent mechanism. This creates a high-risk environment for dangerous hypoglycemia.

Clinical Protocol:
• HbA1c ≤7.5%: Stop the sulfonylurea
• HbA1c 7.6–8.5%: Reduce dose by 50%
• HbA1c >8.5%: Maintain with close monitoring, then taper
Source
ADA Standards of Care in Diabetes—2025; PMC: "Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a GLP-1 Agonist." ADA Guidelines
🚫
DPP-4 Inhibitors (Sitagliptin, Saxagliptin, Linagliptin)
Therapeutic Redundancy — Stop DPP-4
Why They Don't Work Together

DPP-4 inhibitors increase endogenous GLP-1 by 2-3x. GLP-1 receptor agonists provide 8-10x pharmacological activity. Once receptors are saturated by the agonist, the DPP-4 inhibitor adds nothing—just cost and pill burden.

Action: Discontinue DPP-4 inhibitor when starting GLP-1 therapy.
✅
SGLT2 Inhibitors & Metformin
Safe Combination — Recommended
The Benefit

SGLT2 + GLP-1 is strongly recommended by ADA 2025 guidelines for patients with cardiovascular disease, heart failure, or CKD. Complementary mechanisms, additive benefits.

Metformin + GLP-1 has no pharmacokinetic interaction. Standard combination therapy. Only concern: cumulative GI side effects (both cause nausea). Consider metformin ER during GLP-1 titration.

Hydration Warning: SGLT2s are osmotic diuretics. GLP-1s reduce thirst and can cause vomiting. Together, this increases dehydration and AKI risk—counsel patients to maintain fluid intake.

Oral Medication Timing: Absorption Effects

GLP-1s slow gastric emptying—that's how they work. This delay affects the absorption of oral medications: lower peak concentrations (Cmax) and delayed time to peak (Tmax). For most chronic medications, total absorption (AUC) remains the same. But for drugs requiring rapid onset or precise levels, this matters.

⚠️
Oral Contraceptives (Birth Control Pills)
Tirzepatide-Specific Warning
Critical Difference Between Drugs

Tirzepatide (Mounjaro/Zepbound): FDA prescribing information contains a specific warning that tirzepatide may decrease hormonal contraceptive effectiveness.

Semaglutide (Wegovy/Ozempic) & Liraglutide: No clinically significant effect on oral contraceptive bioavailability in studies.

Tirzepatide Protocol: Use a non-oral contraceptive (IUD, implant) OR add barrier method (condoms) for 4 weeks after starting and 4 weeks after each dose increase.
🦋
Levothyroxine (Thyroid Medication)
Monitoring Required
Unexpected Effect

Contrary to other drugs, oral semaglutide (Rybelsus) may increase levothyroxine exposure by ~33%. Delayed gastric emptying may enhance absorption rather than reduce it.

Timing Protocol:
• Injectable GLP-1s: Take levothyroxine 30-60 min before breakfast as usual
• Oral semaglutide: Take Rybelsus upon waking. Wait 30 min. Then take levothyroxine. OR take levothyroxine at bedtime (4+ hours after last meal)
• Monitoring: Check TSH 6-8 weeks after starting GLP-1 or changing dose
🩸
Warfarin (Blood Thinner)
INR Monitoring Required
The Risk

Delayed gastric emptying alters warfarin absorption kinetics. Case reports document significant INR fluctuations—both too high and too low—when starting tirzepatide or semaglutide.

Protocol: Increase INR monitoring frequency during GLP-1 initiation and dose escalation. Anticipate potential warfarin dose adjustments. DOACs (apixaban, rivaroxaban) are less affected but still warrant attention in patients with major weight changes.
Source
PMC: "Drug-Drug Interactions Between GLP-1 Receptor Agonists and Oral Medications: A Systematic Review." 2024. PubMed

Other Oral Medications

Blood Pressure Medications: No direct interaction, but as patients lose weight, blood pressure naturally drops. Antihypertensive doses often need to be reduced—"deprescribing" is common.

Antibiotics: Absorption may be delayed. For time-dependent antibiotics, this is less critical than for concentration-dependent ones. Consider separating antibiotic dose by 1+ hour before GLP-1 injection if daily formulation.

Pain Medications (Acetaminophen, NSAIDs): GLP-1s delay acetaminophen absorption—onset of pain relief may be slower. For NSAIDs, the concern is renal: GLP-1s can cause volume depletion (vomiting/diarrhea), and NSAIDs constrict renal blood vessels. Together, they increase acute kidney injury risk.

Psychiatric Medications (SSRIs, SNRIs): Absorption may be delayed during titration. Monitor for breakthrough symptoms but dose adjustments rarely needed.

Absolute Contraindications

Do NOT Use GLP-1s If You Have:

Alcohol Interactions

Alcohol doesn't neutralize GLP-1s biochemically, but there are important considerations:

Hypoglycemia Risk: Alcohol inhibits the liver's ability to produce glucose. Combined with insulin or sulfonylureas plus GLP-1, this significantly increases delayed hypoglycemia risk.

Emerging Research (2024-2025): Studies suggest GLP-1s may slow alcohol metabolism by affecting gastric emptying and potentially reducing enzyme activity. Patients might feel "less drunk" subjectively (dampened reward signaling) while blood alcohol levels remain elevated longer. GLP-1s are also being studied for hepatoprotection in alcohol-related liver disease.

Practical Guidance: Moderate alcohol intake while on GLP-1s requires caution. Avoid heavy drinking, especially if also on insulin or sulfonylureas.

Quick Reference: Interaction Summary

Drug Class Interaction Action
Insulin Hypoglycemia risk Reduce dose by ~20% if A1c <8%
Sulfonylureas Hypoglycemia risk Stop or reduce by 50%
DPP-4 Inhibitors Therapeutic redundancy Discontinue DPP-4
Birth Control Pills Reduced absorption (tirzepatide) Backup method × 4 weeks after dose changes
Levothyroxine Altered absorption Separate timing; check TSH at 6-8 weeks
Warfarin INR fluctuations Increase INR monitoring frequency
SGLT2 Inhibitors Complementary; dehydration risk Safe combo; maintain hydration
Metformin Additive GI side effects Consider ER formulation; no dose change
The Bottom Line
GLP-1 interactions are mostly pharmacodynamic (additive glucose-lowering causing hypoglycemia) or physiological (slowed gastric emptying affecting oral drug absorption). The highest-risk combinations are with insulin and sulfonylureas—both require dose reductions. Tirzepatide has a specific birth control warning that semaglutide doesn't. For most other oral medications, timing separation and monitoring are sufficient. Always inform all your prescribers that you're on a GLP-1.
Sources
  1. FDA. Wegovy (semaglutide) Prescribing Information. 2021.
  2. FDA. Mounjaro/Zepbound (tirzepatide) Prescribing Information. 2022/2023.
  3. American Diabetes Association. Standards of Care in Diabetes—2025.
  4. PMC. "Drug-Drug Interactions Between GLP-1 Receptor Agonists and Oral Medications: A Systematic Review." 2024.
  5. PMC. "Reducing or Discontinuing Insulin or Sulfonylurea When Initiating a GLP-1 Agonist." 2024.
  6. Reproductive Health Access Project. "Contraceptive Pearl: Drug Interaction Between GLP-1 Agonist and Oral Contraceptives."
  7. Drugs.com. Levothyroxine and Semaglutide Interactions.
  8. PMC. "Tirzepatide-Warfarin Interaction in Mechanical Valve Patient." Case report.
  9. NHS SPS. "Considerations and Interactions with GLP-1 Receptor Agonists."
  10. Yale Medicine. "GLP-1 Receptor Agonists Protect the Liver During Alcohol Consumption." 2024.
  11. GoodRx. "Mounjaro Drug Interactions."
  12. FDA. Ozempic (semaglutide) Prescribing Information. 2017, updated 2024.
  13. StatPearls. "Glucagon-Like Peptide-1 Receptor Agonists."
  14. Cleveland Clinic Consult QD. "Glucagon-Like Peptide-1 Receptor Agonists and Pancreatitis."
  15. PMC. "GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption." 2024.
  16. NIDDK. "Changes to the Standards of Care in Diabetes—2025."
  17. Drugs.com. "Ozempic and Warfarin Interactions Checker."
  18. LifeMD. "Wegovy Drug Interactions You Need to Know About."